BR0107943A - Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos - Google Patents

Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos

Info

Publication number
BR0107943A
BR0107943A BR0107943-3A BR0107943A BR0107943A BR 0107943 A BR0107943 A BR 0107943A BR 0107943 A BR0107943 A BR 0107943A BR 0107943 A BR0107943 A BR 0107943A
Authority
BR
Brazil
Prior art keywords
methods
internal ribosome
identifying
ribosome entry
regulatory elements
Prior art date
Application number
BR0107943-3A
Other languages
English (en)
Inventor
Vincent P Mauro
Gerald M Edelman
Stephen A Chappell
Geoffrey Owens
Jason K Pinkstaff
Leslie Krushel
Wei Zhou
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BR0107943A publication Critical patent/BR0107943A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Abstract

"SìTIOS DE ENTRADA DE RIBOSSOMA INTERNOS SINTéTICOS E MéTODOS DE IDENTIFICAR OS MESMOS". Elementos reguladores translacionais isolados e sintéticos, incluindo oligonucleotídeos que têm atividade de realce translacional, atividade de sítio de entrada de ribossoma interno (IRES), ou atividade inibidora translacional, e multímeros de tais elementos reguladores translacionais são fornecidos. Além disso, composições que incluem tais elementos reguladores translacionais são fornecidas, assim como são os métodos de emprego dos elementos reguladores translacionais.
BR0107943-3A 2000-01-28 2001-01-26 Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos BR0107943A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17881600P 2000-01-28 2000-01-28
US18649600P 2000-03-02 2000-03-02
US20780400P 2000-05-30 2000-05-30
US23095600P 2000-09-07 2000-09-07
US23085200P 2000-09-07 2000-09-07
US26131201P 2001-01-12 2001-01-12
PCT/US2001/002586 WO2001055369A1 (en) 2000-01-28 2001-01-26 Synthetic internal ribosome entry sites and methods of identifying same

Publications (1)

Publication Number Publication Date
BR0107943A true BR0107943A (pt) 2003-01-28

Family

ID=27558689

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0107943-3A BR0107943A (pt) 2000-01-28 2001-01-26 Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos
BR0107930-1A BR0107930A (pt) 2000-01-28 2001-01-26 Métodos de identificação de elementos reguladores transcricionais e translacionais sintéticos, e composições relativas aos mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0107930-1A BR0107930A (pt) 2000-01-28 2001-01-26 Métodos de identificação de elementos reguladores transcricionais e translacionais sintéticos, e composições relativas aos mesmos

Country Status (6)

Country Link
US (3) US7183395B2 (pt)
EP (2) EP1259602A1 (pt)
AU (4) AU3117101A (pt)
BR (2) BR0107943A (pt)
CA (2) CA2398541A1 (pt)
WO (2) WO2001055369A1 (pt)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1259602A1 (en) * 2000-01-28 2002-11-27 The Scripps Research Institute Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same
DE10049587A1 (de) 2000-10-06 2002-05-02 Icon Genetics Ag Vektorsystem für Pflanzen
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
EP1370686A2 (en) * 2001-03-01 2003-12-17 Cistem Molecular Corporation Methods for global profiling gene regulatory element activity
CN1596306A (zh) * 2001-03-07 2005-03-16 荧合金股份有限公司 用于将dna导入靶细胞的筛选方法
EP1373885A4 (en) * 2001-03-29 2004-06-23 Evogene Ltd METHODS, PLATFORMS AND KITS SUITABLE FOR IDENTIFYING, ISOLATING AND USING GENE EXPRESSION IN AN ORGANISM REGULATING NUCLEOTIDE SEQUENCES
DE10121283B4 (de) 2001-04-30 2011-08-11 Icon Genetics GmbH, 80333 Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
DE10143238A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente
NZ532060A (en) * 2001-10-02 2005-11-25 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications
US20080076678A1 (en) 2005-06-15 2008-03-27 Philippe Soucaille Method of creating a library of bacterial clones with varying levels of gene expression
AU2003285844A1 (en) * 2002-11-12 2004-06-03 Zakrytoe Aktsionernoe Obschestvo "Evrogen" Fluorescent proteins and chromoproteins from non-aequorea hydrozoa species and methods for using same
AU2004219858B2 (en) 2003-03-12 2009-01-08 Evogene Ltd. Nucleotide sequences regulating gene expression and constructs and methods utilizing same
US20050037409A1 (en) * 2003-07-29 2005-02-17 Kauvar Lawrence M. Translocation tagging
US8293503B2 (en) 2003-10-03 2012-10-23 Promega Corporation Vectors for directional cloning
EP1685247B1 (en) * 2003-10-03 2009-11-11 Promega Corporation Vectors for directional cloning
CA2562893A1 (en) * 2004-04-28 2005-11-10 The Trustees Of The University Of Pennsylvania Polyvalent viral vectors and a system for production thereof
US7709625B2 (en) * 2004-06-10 2010-05-04 The Board Of Regents Of The University Of Texas Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy
JP5225087B2 (ja) * 2005-08-24 2013-07-03 ザ スクリプス リサーチ インスティチュート 翻訳エンハンサーエレメント依存性のベクター系
WO2007025190A2 (en) * 2005-08-25 2007-03-01 Whitehead Institute For Biomedical Research Novel methods for genome-wide location analysis
WO2007038757A2 (en) * 2005-09-28 2007-04-05 Attagene Inc. Methods and compositions for non-invasive assessment of gene expression
WO2007097443A1 (ja) * 2006-02-20 2007-08-30 National University Corporation Hokkaido University Ｄｎａ塩基配列を決定する方法
WO2008005310A2 (en) * 2006-06-30 2008-01-10 Ambit Biosciences Corp. Detectable nucleic acid tag
CA2735575A1 (en) * 2007-08-10 2009-02-19 Wayne State University Compositions and methods for detecting and modulating cell death by a translation regulated gene expression system
KR101541935B1 (ko) * 2007-09-26 2015-08-05 인트렉손 코포레이션 합성 5'ｕｔｒ, 발현 벡터, 및 전이유전자 발현의 증가방법
CA2904904A1 (en) * 2007-12-11 2009-06-18 The Scripps Research Institute Compositions and methods related to mrna translational enhancer elements
WO2010096594A2 (en) 2009-02-18 2010-08-26 Wayne State University Method for identifying a subpopulation of mammalian cells with distinctive ribosome translation profiles
JP2012524907A (ja) 2009-04-24 2012-10-18 ディスカヴァーエックス コーポレイション 検出可能なタンパク質を用いた細胞分析
US20130230884A1 (en) * 2010-07-16 2013-09-05 John Chaput Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation
US20130244231A1 (en) * 2010-11-08 2013-09-19 Jcr Pharmaceuticals Co., Ltd. Novel expression vector
EP2705152B1 (en) * 2011-05-04 2017-10-25 The Broad Institute, Inc. Multiplexed genetic reporter assays and compositions
CN102517282B (zh) * 2011-12-30 2013-10-30 中国人民解放军军事医学科学院放射与辐射医学研究所 一种富集分离内源转录因子及其复合物的方法及其专用转录因子串联结合序列
US20140107589A1 (en) * 2012-10-17 2014-04-17 Farid Amirouche Electromagnetically actuated valve and related methods of use
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
WO2014113089A2 (en) 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP2801622A1 (en) * 2013-05-08 2014-11-12 DeltaCell B.V. Multi-tag reporter system
EP2996697B1 (en) * 2013-05-15 2019-06-26 Robert Kruse Intracellular translation of circular rna
HUE058792T2 (hu) * 2013-11-12 2022-09-28 Univ Brussel Vrije RNS-transzkripciós vektor és felhasználása
GB201406006D0 (en) * 2014-04-03 2014-05-21 Norwegian Univ Sci & Tech Ntnu Synthetic mRNA leaders
EP3041948B1 (en) 2014-11-10 2019-01-09 Modernatx, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
AU2016324310B2 (en) 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3350333B1 (en) 2015-09-17 2021-10-27 ModernaTX, Inc. Polynucleotides containing a stabilizing tail region
CA3001003A1 (en) 2015-10-05 2017-04-13 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
EP3362460A1 (en) 2015-10-16 2018-08-22 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
WO2017066781A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
JP7114465B2 (ja) 2015-12-22 2022-08-08 モデルナティエックス インコーポレイテッド 薬剤の細胞内送達のための化合物および組成物
US10689689B2 (en) * 2015-12-28 2020-06-23 Roche Molecular Systems, Inc. Generic method for the stabilization of specific RNA
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017180917A2 (en) 2016-04-13 2017-10-19 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
US20190275170A1 (en) 2016-05-18 2019-09-12 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
DK3458083T3 (da) 2016-05-18 2023-01-30 Modernatx Inc Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
WO2017218704A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
DE102017103383A1 (de) * 2017-02-20 2018-08-23 aReNA-Bio GbR (vertretungsberechtigter Gesellschafter: Dr. Heribert Bohlen, 50733 Köln) System und Verfahren zur Zelltyp-spezifischen Translation von RNA-Molekülen in Eukaryoten
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
AU2018234692B2 (en) 2017-03-15 2022-06-02 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
EP3638678A1 (en) 2017-06-14 2020-04-22 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
WO2019036638A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR PREPARING MODIFIED RNA
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
CN109553686A (zh) * 2017-09-26 2019-04-02 南京安吉生物科技有限公司 一种新型可调控的双嵌合抗原受体t细胞及其构建方法和应用
WO2019140116A2 (en) 2018-01-10 2019-07-18 Rubius Therapeutics, Inc. Amplifiable rnas for therapeutic cell systems
US11875876B2 (en) 2018-06-15 2024-01-16 Massachusetts Institute Of Technology Synthetic 5' UTR sequences, and high-throughput engineering and screening thereof
JP7410135B2 (ja) 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための化合物及び組成物
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
SG11202108098QA (en) 2019-01-31 2021-08-30 Modernatx Inc Vortex mixers and associated methods, systems, and apparatuses thereof
CA3128215A1 (en) 2019-01-31 2020-08-06 Modernatx, Inc. Methods of preparing lipid nanoparticles
EP4054652A4 (en) * 2019-11-07 2023-11-22 Icahn School of Medicine at Mount Sinai SYNTHETIC MODIFIED RNA AND USES THEREOF
CN110819707B (zh) * 2019-11-24 2023-07-18 中南大学湘雅医院 一种针对多种来源细胞样本中内部核糖体结合位点元件的高通量鉴定方法
EP4077272A1 (en) 2020-04-09 2022-10-26 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticle composition
TW202204622A (zh) 2020-04-09 2022-02-01 大陸商蘇州艾博生物科技有限公司 針對冠狀病毒之核酸疫苗
KR20230030588A (ko) 2020-06-30 2023-03-06 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 화합물 및 지질 나노입자 조성물
WO2022020811A1 (en) 2020-07-24 2022-01-27 Strand Therapeutics, Inc. Lipidnanoparticle comprising modified nucleotides
KR20230054672A (ko) 2020-08-20 2023-04-25 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 화합물 및 지질 나노입자 조성물
AR124599A1 (es) 2021-01-08 2023-04-12 Strand Therapeutics Inc Constructos de expresión y usos de estos
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CN116615472A (zh) 2021-01-14 2023-08-18 苏州艾博生物科技有限公司 聚合物缀合的脂质化合物和脂质纳米颗粒组合物
WO2022247755A1 (en) 2021-05-24 2022-12-01 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
AR127312A1 (es) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
AU2022358824A1 (en) 2021-10-08 2024-04-11 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CN116064598B (zh) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
WO2024037578A1 (en) 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
EP0706319A4 (en) * 1993-01-20 1998-04-22 Biotransplant Inc RETROVIRAL VECTORS WITH THE ABILITY TO EXPRESS MULTIMERAL PROTEINS FROM MULTIPLE TRANSLATION INITIATION LOCATIONS
US5686120A (en) * 1995-05-22 1997-11-11 Wisconsin Alumni Research Foundation Pre-mRNA processing enhancer and method for intron-independent gene expression
CA2205888A1 (en) 1997-07-11 1999-01-11 John J. Priatel Complementation trap
CA2309000A1 (en) * 1997-11-13 1999-05-27 Regents Of The University Of Minnesota Tc1-based transposon vectors
EP1259602A1 (en) * 2000-01-28 2002-11-27 The Scripps Research Institute Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same

Also Published As

Publication number Publication date
WO2001055371A1 (en) 2001-08-02
EP1274838A1 (en) 2003-01-15
US7456273B2 (en) 2008-11-25
US7183395B2 (en) 2007-02-27
US20070270580A1 (en) 2007-11-22
AU2001231171B2 (en) 2007-01-04
AU3117101A (en) 2001-08-07
AU3120601A (en) 2001-08-07
US20090093049A1 (en) 2009-04-09
WO2001055369A9 (en) 2002-10-31
EP1259602A1 (en) 2002-11-27
CA2398790A1 (en) 2001-08-02
BR0107930A (pt) 2004-06-15
AU2001231171B8 (en) 2001-08-07
US20040005564A1 (en) 2004-01-08
CA2398541A1 (en) 2001-08-02
AU2007202122A1 (en) 2007-05-31
WO2001055369A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
BR0107943A (pt) Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos
BRPI0411078A (pt) ligantes de receptores de canabinóides e seus usos
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
HN1996000017A (es) Isotiazolonas
ES2146774T3 (es) Polimeros de ioneno que contienen aniones biologicamente activos.
DK0889886T5 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
ATE268547T1 (de) Auf tensiden basierende antimikrobielle zusammensetzungen und verfahren zu ihrer verwendung
BRPI0410289A (pt) ligantes do receptor de canabinóides e suas utilizações
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
PT942904E (pt) Derivados de 3-tiocarbamoilpirazol como pesticidas
TR200002616T2 (tr) Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
TR200100918T2 (tr) Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
DK0882021T3 (da) Nye phenanthridiner
NO20052928L (no) Nye kjemiske forbindelser
BRPI0414918A (pt) compostos de benzoimidazola
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
DE69717101D1 (de) VERWENDUNG VON alpha-ALKYLGLUCOSIDEN UND DEREN ESTERN ALS ANTIMIKROBIELLE EMULGATOREN
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE346147T1 (de) Zusammensetzungen und methoden zur wundheilung
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained